Autoimmune/Cholestatic/Biliary Diseases News

Fecal microbiota transplant, regardless of dose or route, was safe and associated with reduced hepatic encephalopathy recurrence among patients with cirrhosis receiving lactulose and rifaximin, according to a study in Journal of Hepatology.

Injectable naltrexone had a more favorable gastrointestinal and liver safety profile compared with other medications for alcohol use disorder, according to a research letter published in Clinical Gastroenterology and Hepatology.

Oral vancomycin therapy resulted in clinical response in nearly half of patients with inflammatory bowel disease associated with primary sclerosing cholangitis, according to a study published in Therapeutic Advances in Gastroenterology.

The FDA has granted Cour Pharmaceuticals orphan drug designation for CNP-104, a biodegradable nanoparticle in development for the treatment of primary biliary cholangitis, the company announced in a press release.

Eight years ago, Ocaliva was a prospective lifesaver for patients with primary biliary cholangitis who failed to adequately respond to first-line ursodeoxycholic acid. However, the once-promising drug now finds itself struggling to deliver.

The FDA has issued a safety alert warning that obeticholic acid carries an increased risk for “serious liver injury” among patients with primary biliary cholangitis, even those without advanced cirrhosis.

SAN DIEGO — A new ultrasound approach may help more quickly and less invasively identify infants with biliary atresia, according to research presented at The Liver Meeting.

SAN DIEGO — Patients with primary biliary cholangitis who were incomplete responders to obeticholic acid may still demonstrate improvement in inflammatory markers and fibrosis scores, according to research presented at The Liver Meeting.

SAN DIEGO — Livdelzi appeared safe and well-tolerated and reduced markers of cholestasis and liver injury in patients with primary biliary cholangitis, including those with compensated cirrhosis, according to a presenter.